Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.
-
Easy Environmental Solutions surges to great start in first quarter of 2026
-
Cbio gets EMA approval to start its phase I/IIa clinical trial in late stage cancer patients with novel T-cell product armored against oxidative stress
-
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
-
AI, healthcare technology, and digital infrastructure is a central theme dominating markets: the rapid convergence of AI with data-heavy industries
-
Unicorns are usually $1 billion private companies, backed by institutional players and Kraig Labs (OTCQB: KBLB) is advancing a $billion platform
-
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its...
-
Vancouver, Canada, March 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and...
-
— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being...
-
Commit Biologics appoints seasoned biotech entrepreneur Thomas L. F. Montgomery Andresen, PhD, as Chief Executive Officer.